Cell Therapy Durability Response Summit USA 2022

Cell Therapy Durability Response

Next Generation Engineering Strategies to Deliver Persistent, Efficacious, Safe Cell Therapy Products

Download 2022 Agenda
Boston, USA
22-23 August, 2022

“I thought it was well organized, and a nice size for networking and discussion, and the quality of the presentations was high”

James Tasker, Ziopharm Oncology (Onco Cell Therapy Summit USA 2021 attendee)

Why Attend

The current generation of CAR-T approaches for hematological malignancies generate strong responses in cancer patients, but too often progression-free survival is less than 12 months. The next-generation allogeneic approaches may make these therapies more accessible to the patients who need them but have been hampered by poor in vivo persistence. And so far, no cell therapy has been approved to tackle solid tumors, in part due to the immunosuppressive microenvironment and a strong ability for tumor antigen escape, both limiting the durability of therapeutic responses.

Durability is the #1 challenge for cell therapy – the Cell Therapy Durability Response Summit is the first conference to focus on this issue.

AUDIENCE BREAKDOWN

45%
Biotech
25%
Pharma
10%
Academic
20%
Vendors

Biotech

Pharma

Academic

Vendors

OUR CELL THERAPY COMMUNITY

Network with industry experts from:

  • 23+ senior-level speakers
  • Researchers from cell therapy biotechs
  • Representatives from pharmaceutical companies in the cell therapy space
  • Academic experts
  • R&D solution providers

Cell Therapy Series Attendees:

Confirmed 2022 Speakers

 

Vicki Plaks

Sr. Director, Cell Therapy, Oncology Discovery
AbbVie

Vicki Plaks

Sr. Director, Cell Therapy, Oncology Discovery
AbbVie

Vicki Plaks

Sr. Director, Cell Therapy, Oncology Discovery
AbbVie
 

Justin Edwards

Director of Cell Biology
Arcellx

Justin Edwards

Director of Cell Biology
Arcellx

Justin Edwards

Director of Cell Biology
Arcellx
 

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics

Karrie Wong

Director of Cell Therapy
KSQ Therapeutics
 

Jonathan Gilbert

VP of Exploratory Medicine
SQZ Therapeutics

Jonathan Gilbert, PhD joined SQZ in 2013 and has been a key player in the growth and development of the company from its formative stages. As the Vice President of Exploratory Research, he is applying the Cell Squeeze Technology to generate new cell therapy concepts in multiple disease areas from cancer to regenerative medicine. In previous roles he lead Business Development as well as managing active partnerships such as the >$1B Collaboration with Roche. Dr.

Jonathan Gilbert

VP of Exploratory Medicine
SQZ Therapeutics

Jonathan Gilbert

VP of Exploratory Medicine
SQZ Therapeutics

Jonathan Gilbert, PhD joined SQZ in 2013 and has been a key player in the growth and development of the company from its formative stages. As the Vice President of Exploratory Research, he is applying the Cell Squeeze Technology to generate new cell therapy concepts in multiple disease areas from cancer to regenerative medicine. In previous roles he lead Business Development as well as managing active partnerships such as the >$1B Collaboration with Roche. Dr. Gilbert received his PhD in Chemical Engineering from MIT, where he was a Presidential Fellow, and studied biomedical applications of structured polyelectrolyte films with Professor Robert Cohen and Professor Michael Rubner. He has published over a dozen articles and is an inventor on 8 patents.

 

Samia Khan

Senior Scientist
Editas Medicine

Samia Khan

Senior Scientist
Editas Medicine

Samia Khan

Senior Scientist
Editas Medicine
 

Krishnan Viswanadhan

Chief Operating Officer
Be Biopharma

Dr. Krishnan Viswanadhan is a biopharmaceutical executive with over 20 years of broad cross-functional experience in advancing new medicines for patients with serious and life-threatening diseases. Krishnan is currently President and Chief Operating Officer at Be Biopharma, a leader in engineered B cells as a new category of medicines for patients with serious diseases.  

Krishnan Viswanadhan

Chief Operating Officer
Be Biopharma

Krishnan Viswanadhan

Chief Operating Officer
Be Biopharma

Dr. Krishnan Viswanadhan is a biopharmaceutical executive with over 20 years of broad cross-functional experience in advancing new medicines for patients with serious and life-threatening diseases. Krishnan is currently President and Chief Operating Officer at Be Biopharma, a leader in engineered B cells as a new category of medicines for patients with serious diseases.  

Prior to Be Bio, Krishnan was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb where he was responsible for overseeing the integrated cell therapy franchise strategy across the enterprise including building core capabilities and key investments to support long term growth. He oversaw the teams responsible for the development, approval, and life cycle management of Breyanzi, a CD19 CAR T and Abecma, the first BCMA CAR T therapy. 

Prior to BMS, Krishnan was Vice President, Business Development and Global Alliances at Celgene Corporation responsible for managing the portfolio of partnerships and equity investments. Prior to Celgene, Krishnan had roles in large and small companies in regulatory strategy. 

Dr. Viswanadhan is a registered Pharmacist and received his Doctor of Pharmacy degree from Rutgers University and holds a Master of Business Administration degree from Cornell University.

 

Krishnan currently serves the board as a non-executive director of JW Therapeutics, a leading cell therapy company in China. 

 

David Barrett

Vice President Translational Research
Tmunity Therapeutics

Dr. Barrett first completed a Master of Science in Biomedical Engineering in 1997 before going on to complete his combined MD/PhD (Molecular Biology and Genetics) at Virginia Commonwealth University in 2004.  He moved to the Children’s Hospital of Philadelphia for his residency in pediatrics, completed in 2007, and his fellowship in pediatric hematology/oncology, which he finished in 2010.

David Barrett

Vice President Translational Research
Tmunity Therapeutics

David Barrett

Vice President Translational Research
Tmunity Therapeutics

Dr. Barrett first completed a Master of Science in Biomedical Engineering in 1997 before going on to complete his combined MD/PhD (Molecular Biology and Genetics) at Virginia Commonwealth University in 2004.  He moved to the Children’s Hospital of Philadelphia for his residency in pediatrics, completed in 2007, and his fellowship in pediatric hematology/oncology, which he finished in 2010. He was an Assistant Professor in Pediatrics at the University of Pennsylvania and an attending physician in the Children’s Hospital of Philadelphia Division of Oncology, Transplant and Cellular Therapy Section until 2020.  He is now Vice President of Translational Research at Tmunity Therapeutics.

 

Dr. Barrett is interested in the translational development of immune therapies for pediatric cancers.  He participated in some of the preclinical development of the product that became Kymriah, and remembers well how much we learned from the first pediatric patient to be treated.  He went on to work on the preclinical development of not only CARs for CD19 (mouse and humanized), but also CD22, GD2, GPC2, CD2, CD5, CD7, CD123, CD38 and even an anti-CAR CAR.  In his lab at CHOP, he also focused on translational research from patient samples, focusing on features of the starting material for CAR manufacture that led to better clinical outcomes with Kymriah.

 

Mariska ter Haak

Director, Analytical Development
IN8bio

Mariska ter Haak

Director, Analytical Development
IN8bio

Mariska ter Haak

Director, Analytical Development
IN8bio
 

Geoff Hodge

CEO
SOTIO Biotech US

 

Geoff is the CEO of SOTIO Biotech US, a Cambridge, MA based subsidiary of SOTIO Biotech a.s. that is focused on the development of novel cell therapies to treat solid tumor cancers. He has over 30 years of experience in the biotechnology industry, providing bioprocessing technical solutions for companies including GE Healthcare Life Sciences (Cytiva), Millennium Pharmaceuticals (Takeda), Genetics Institute (Wyeth/Pfizer) and Alpha-Beta Technology. He is an inventor on more than a dozen bioprocess equipment and technology patents.

 

Geoff Hodge

CEO
SOTIO Biotech US

Geoff Hodge

CEO
SOTIO Biotech US

 

Geoff is the CEO of SOTIO Biotech US, a Cambridge, MA based subsidiary of SOTIO Biotech a.s. that is focused on the development of novel cell therapies to treat solid tumor cancers. He has over 30 years of experience in the biotechnology industry, providing bioprocessing technical solutions for companies including GE Healthcare Life Sciences (Cytiva), Millennium Pharmaceuticals (Takeda), Genetics Institute (Wyeth/Pfizer) and Alpha-Beta Technology. He is an inventor on more than a dozen bioprocess equipment and technology patents.

 

Prior to SOTIO, Geoff was Chief Technical Officer at Unum Therapeutics, where he managed all technical operations for the company—including process and analytical development, manufacturing, and quality—for the company’s clinical phase viral vector and T-cell processes, as well as overseeing corporate IT, facilities, and logistics. He was previously a co-founder of Xcellerex, a company pioneering single-use bioreactors, mixers, facilities, and GMP manufacturing services, featuring single-use manufacturing and high-throughput process development services. He is the inventor of record on multiple core technology patents for Xcellerex, and served as an operations leader at GE Healthcare Life Sciences after GE acquired Xcellerex. Geoff holds an M.S. in Biotechnology from WPI and Bachelor’s degree in Biology from Colgate University.

 

 

Monique Dao

VP, Translational Medicine, Immunology
bit.bio

Monique Dao

VP, Translational Medicine, Immunology
bit.bio

Monique Dao

VP, Translational Medicine, Immunology
bit.bio
 

Stefanie Mandi

SVP Translational Research
PACT Pharma

Stefanie Mandi

SVP Translational Research
PACT Pharma

Stefanie Mandi

SVP Translational Research
PACT Pharma
 

John Rossi

Senior Vice President, Head of Translational Medicine
CERo Therapeutics

John Rossi

Senior Vice President, Head of Translational Medicine
CERo Therapeutics

John Rossi

Senior Vice President, Head of Translational Medicine
CERo Therapeutics
 

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic
 

Marc Davies

VP, CAR Engineering
Leucid Bio

Marc Davies

VP, CAR Engineering
Leucid Bio

Marc Davies

VP, CAR Engineering
Leucid Bio
 

Robert Brooks

CEO
Alphageneron Pharmaceuticals

Robert Brooks

CEO
Alphageneron Pharmaceuticals

Robert Brooks

CEO
Alphageneron Pharmaceuticals
 

Ben Wang

Co-Founder
Chimera Bioengineering

Ben Wang

Co-Founder
Chimera Bioengineering

Ben Wang

Co-Founder
Chimera Bioengineering
 

Frank Borriello

Scientific Founder & Chief Executive Officer
Alloplex Biotherapeutics

Frank Borriello

Scientific Founder & Chief Executive Officer
Alloplex Biotherapeutics

Frank Borriello

Scientific Founder & Chief Executive Officer
Alloplex Biotherapeutics
 

Andrew Weinberg

President and CSO
AgonOx

In recent years we have been defining T cell populations within the blood and tumor of cancer patients to determine potential protein/pathways that could specifically target TIL therapeutically.  Our initial publication compared T cells from patients with colorectal liver metastatses and ovarian cancer.  We found several differences in the phenotype of CD8s, CD4s, and Tregs between the TIL and blood that were consistent between these two different types of tumors.  This suggested to us that two distinct tumor types were behaving very similar immunologically, hence one coul

Andrew Weinberg

President and CSO
AgonOx

Andrew Weinberg

President and CSO
AgonOx

In recent years we have been defining T cell populations within the blood and tumor of cancer patients to determine potential protein/pathways that could specifically target TIL therapeutically.  Our initial publication compared T cells from patients with colorectal liver metastatses and ovarian cancer.  We found several differences in the phenotype of CD8s, CD4s, and Tregs between the TIL and blood that were consistent between these two different types of tumors.  This suggested to us that two distinct tumor types were behaving very similar immunologically, hence one could potentially target them with the same immunotherapy agents (e.g. PD-1 blockade works for several different tumor types).  With this in mind we have found several new protein targets that we are exploring as therapeutic targets preclinically with this approach.  Upon further inspection with other tumor types and a deeper dive into the CD8 phenotype in tumors vs blood we discovered a unique CD8 T cell population that express both CD39 and CD103.  These T cells were only found in tumors and were highly enriched for tumor-reactivity.  The CD39/103 double CD8 TIL had both an activated and exhausted phenotype, suggesting that they had recently encountered the tumor Ag in situ.  Another unique finding was the highly clonal nature of these CD8 TIL when assessed directly ex vivo and these clones were found at very low frequency in the blood of cancer patients.  The data suggested that these cells make it into the tumor microenvironment and expand when they encounter their tumor Ag; however, chronic activation in the tumor might lead to exhaustion of this CD8 TIL population.  We have now been able to rescue/grow these cells in vitro and expand them from thousands of cells to billions in a 4-week span.  We have found that they can kill autologous tumors in vitro and make autologous tumors completely regress in tumor-bearing mice.  This data has set the stage for an adoptive T cell therapy clinical trial and will be performed with this tumor-reactive T cell population.  Our group has had a pre-IND discussion with the FDA earlier this year and are currently performing 3 qualifying runs, which should be completed by Jan 2022.  We intend to submit the IND for this clinical trial in early 2022 and commence with the trial soon thereafter.  

 

Raphaël Ognar

CEO & Co-Founder
NKILT Therapeutics

Raphaël Ognar

CEO & Co-Founder
NKILT Therapeutics

Raphaël Ognar

CEO & Co-Founder
NKILT Therapeutics
 

Austin Bigley

VP of Research and Development
Indapta Therapeutics

Austin Bigley

VP of Research and Development
Indapta Therapeutics

Austin Bigley

VP of Research and Development
Indapta Therapeutics
 

Avlad Pato

Head of Research, Natural Killer Cells
Gamida Cell

Avlad Pato

Head of Research, Natural Killer Cells
Gamida Cell

Avlad Pato

Head of Research, Natural Killer Cells
Gamida Cell
 

Michael O'Dwyer

Chief Scientific Officer
ONK Therapeutics

Michael O'Dwyer

Chief Scientific Officer
ONK Therapeutics

Michael O'Dwyer

Chief Scientific Officer
ONK Therapeutics

Get The Agenda

What to expect:

  • Discussion of the source of durability challenges, and consideration of varied solutions
  • Exploration of new receptor design and cell engineering strategies for αβT cells to improve durability, including multi-targeted approaches, polyclonal therapeutics, and regulation by synthetic biology
  • Enhancing NK cells through gene editing to drive greater persistence and efficacy in vivo
  • Talks on alternative cell types, including red blood cells, B cells, δγT cells and myeloid cells


Download Agenda

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact Ryan Sanderson, Commercial Partnerships Director at [email protected] or register your interest here.

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

2022 PARTNERS

Gold Sponsor

Event Partner

CONFERENCE PACKAGES

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, June 11, 2022 to Friday, July 22, 2022
Tier 1 - Academics
$999
Early Bird pricing until July 22! Register now and save up to $300
Saturday, June 11, 2022 to Friday, July 22, 2022
Tier 2 - Biotech & Pharma
$2,099
Early Bird pricing until July 22! Register now and save up to $300
Saturday, June 11, 2022 to Friday, July 22, 2022
Tier 3 - Industry/Service Provider
$3,199
Early Bird pricing until July 22! Register now and save up to $300
Preparing registration...

Venue Description

Venue

Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, United States

To book a discounted room in the hotel, please click here.

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Resources

Download Resource

Venue

Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, United States

To book a discounted room in the hotel, please click here.

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us